These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27668396)

  • 1. Radical Hysterectomy Plus Concurrent Chemoradiation/Radiation Therapy Is Negatively Associated With Return to Work in Patients With Cervical Cancer.
    Nakamura K; Masuyama H; Ida N; Haruma T; Kusumoto T; Seki N; Hiramatsu Y
    Int J Gynecol Cancer; 2017 Jan; 27(1):117-122. PubMed ID: 27668396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.
    Huang H; Feng YL; Wan T; Zhang YN; Cao XP; Huang YW; Xiong Y; Huang X; Zheng M; Li YF; Li JD; Chen GD; Li H; Chen YL; Ma LG; Yang HY; Li L; Yao SZ; Ye WJ; Tu H; Huang QD; Liang LZ; Liu FY; Liu Q; Liu JH
    JAMA Oncol; 2021 Mar; 7(3):361-369. PubMed ID: 33443541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
    Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
    BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).
    Nakamura K; Kitahara Y; Satoh T; Takei Y; Takano M; Nagao S; Sekiguchi I; Suzuki M
    World J Surg Oncol; 2016 Jun; 14(1):173. PubMed ID: 27356862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes in patients with FIGO stage IB-IIA cervical cancer and a focally disrupted cervical stromal ring on magnetic resonance imaging: A propensity score matching study.
    Kong TW; Lee JD; Son JH; Paek J; Chun M; Chang SJ; Ryu HS
    Gynecol Oncol; 2016 Oct; 143(1):77-82. PubMed ID: 27423377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Role of Adjuvant Chemotherapy after Radical Hysterectomy for FIGO Stage IB-IIA Cervical Cancer: Comparison with Adjuvant RT/CCRT Using Inverse-Probability-of-Treatment Weighting.
    Jung PS; Kim DY; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    PLoS One; 2015; 10(7):e0132298. PubMed ID: 26176626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
    Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
    J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative concurrent daily low-dose cisplatin-based chemoradiation improves the prognosis of patients with pathologic T2b or N1 cervical cancer.
    Mitsuhashi A; Uno T; Usui H; Tate S; Hirashiki K; Kato K; Kiyohara H; Kato S; Ito H; Shozu M
    Anticancer Res; 2010 Jun; 30(6):2341-6. PubMed ID: 20651390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcomes for patients with cervical cancer who developed bone metastasis after the primary treatment with concurrent chemoradiation versus radiation therapy alone.
    Nartthanarung A; Thanapprapasr D
    Int J Gynecol Cancer; 2010 Nov; 20(8):1386-90. PubMed ID: 21051982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer.
    Yin M; Zhao F; Lou G; Zhang H; Sun M; Li C; Hou Y; Li X; Meng F; Chen X
    Int J Gynecol Cancer; 2011 Jan; 21(1):92-9. PubMed ID: 21330834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients.
    Ryu HS; Chun M; Chang KH; Chang HJ; Lee JP
    Gynecol Oncol; 2005 Feb; 96(2):490-5. PubMed ID: 15661240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI.
    Nam H; Park W; Huh SJ; Bae DS; Kim BG; Lee JH; Lee JW; Lim DH; Han Y; Park HC; Ahn YC
    Gynecol Oncol; 2007 Nov; 107(2):320-5. PubMed ID: 17675222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.
    Chen SW; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yang SN; Lin FJ
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1370-7. PubMed ID: 16979836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
    Liu B; Li L; Wang M; Wei L; Li J; Zou W; Lv Y; Zhang H; Liu S
    Gynecol Oncol; 2019 Sep; 154(3):583-589. PubMed ID: 31307665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 20 year experience of postoperative radiotherapy in IB-IIA cervical cancer patients with intermediate risk factors: impact of treatment period and concurrent chemotherapy.
    Song S; Song C; Kim HJ; Wu HG; Kim JH; Park NH; Song YS; Kim JW; Kang SB; Ha SW
    Gynecol Oncol; 2012 Jan; 124(1):63-7. PubMed ID: 22004904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of various treatment modalities on the outcome of stage IB1-IIA cervical adenocarcinoma.
    Chen YL; Ho CM; Chen CA; Chiang YC; Huang CY; Hsieh CY; Cheng WF
    Int J Gynaecol Obstet; 2011 Feb; 112(2):135-9. PubMed ID: 21130445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.